Skip to main content
SpringerLink
Log in

Ergebnisse einer randomisierten Phase-III-Studie zur Behandlung rezidivierter Glioblastome

NovoTTF-100A versus Chemotherapie

Results of a randomized phase III study on treatment of recurrent glioblastoma

NovoTTF-100A versus chemotherapy

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Dresemann G, Weller M, Rosenthal MA et al (2010) Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 96:393–402

    Article  PubMed  CAS  Google Scholar 

  2. Minniti G, Armosini V, Salvati M et al (2011) Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 103:683–691

    Article  PubMed  CAS  Google Scholar 

  3. Niyazi M, Ganswindt U, Schwarz SB et al (2012) Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 82:67–76

    Article  PubMed  CAS  Google Scholar 

  4. Prados MD, Schold SC, Fine HA et al (2003) A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol 5:96–103

    PubMed  CAS  Google Scholar 

  5. Stupp R, Wong ET, Kanner AA et al (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192–2202

    Article  PubMed  Google Scholar 

  6. Bent MJ van den, Brandes AA, Rampling R et al (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27:1268–1274

    Article  PubMed  Google Scholar 

  7. Wick W, Puduvalli VK, Chamberlain MC et al (2012) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168–1174

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norwegen

    C. Nieder M.D.

Authors
  1. C. Nieder M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Nieder M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nieder, C. Ergebnisse einer randomisierten Phase-III-Studie zur Behandlung rezidivierter Glioblastome. Strahlenther Onkol 189, 93–94 (2013). https://doi.org/10.1007/s00066-012-0251-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-012-0251-8

Search

Navigation